On the other hand, it has been suggested that it could have potential applicability for monitoring response to future disease-modifying treatments because there are significant differences in genetic forms of CJD between PRNP mutation carriers and non-carriers years before symptom onset, and levels of test-retest of total PrP are stable during follow-up [79,80]. This evidence concerns the gene PRNP and Creutzfeldt Jacob disease.